What Did US FDA Do Wrong In Its Review Of Aducanumab? AdCom Members Have A List

Nov 08 2020

• By Brenda Sandburg

Listen to this article

Committee members rebuked FDA for its positive review of Biogen’s Alzheimer’s disease drug, objecting to its ‘terrifically one-sided’ analysis of data, the short shrift given the contrary conclusions of its own statistician, and its interpretation of a dosing study to support the sole positive Phase III study.

Abstract mash line and point Question mark. Business illustration. Polygonal low poly — FDA Advisory Committee has many questions about aducanumab Alzheimer's disease drug • Source: Shutterstock

The US Food and Drug Administration faced a barrage of criticism from members of its advisory committee over its positive review of Biogen, Inc.’s aducanumab Alzheimer’s disease drug. They objected to the way the agency laid out data in a joint briefing document with Biogen, saying FDA weighted the findings in favor of the sponsor and downplayed the discordant results of two Phase III studies.

At its 6 November meeting, the Peripheral and Central Nervous System Drugs Advisory Committee voted that Biogen’s single positive Phase...

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says
Sep 11 2024
• By Sue Sutter
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Recent And Upcoming FDA Advisory Committee Meetings
Aug 23 2024
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
EU Filings Tracker TEST
Aug 22 2024
New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.
US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks
Aug 21 2024
• By Sue Sutter
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says
Sep 11 2024
• By Sue Sutter
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Global Pharma Guidance Tracker – August 2024
Sep 09 2024
• By Vibha Sharma
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Recent And Upcoming FDA Advisory Committee Meetings
Aug 23 2024
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.